Wikipedia - Hypertension

Hypertension
Classification and external resources

Automated arm blood pressure meter showing arterial hypertension (shown a systolic blood pressure 158 mmHg, diastolic blood pressure 99 mmHg and heart rate of 80 beats per minute).
ICD-10 I10.,I11.,I12.,
I13.,I15.
ICD-9 401
OMIM 145500
DiseasesDB 6330
MedlinePlus 000468
eMedicine med/1106 ped/1097 emerg/267
MeSH D006973

Hypertension (HTN) or high blood pressure is a chronic medical condition in which the blood pressure in the arteries is elevated. It is classified as either primary (essential) or secondary. About 90-95% of cases are termed "primary hypertension", which refers to high blood pressure for which no medical cause can be found.[1] The remaining 5-10% of cases (Secondary hypertension) are caused by another conditions that affect the kidneys, arteries, heart, or endocrine system.[2]

Persistent hypertension is one of the risk factors for strokes, heart attacks, heart failure and arterial aneurysm, and is a leading cause of chronic kidney failure.[3] Moderate elevation of arterial blood pressure leads to shortened life expectancy. Both dietary and lifestyle changes as well as medicines can improve blood pressure control and decrease the risk of associated health complications.

Contents

[edit] Classification

The variation in pressure in the left ventricle (blue line) and the aorta (red line) over two cardiac cycles ("heart beats"), showing the definitions of systolic and diastolic pressure.
Classification Systolic pressure Diastolic pressure
mmHg kPa mmHg kPa
Normal 90–119 12–15.9 60–79 8.0–10.5
Prehypertension 120–139 16.0–18.5 80–89 10.7–11.9
Stage 1 140–159 18.7–21.2 90–99 12.0–13.2
Stage 2 =160 =21.3 =100 =13.3
Isolated systolic
hypertension
=140 =18.7 <90 <12.0
Source: American Heart Association (2003).[4]

Blood pressure is usually classified based on the systolic and diastolic blood pressures. Systolic blood pressure is the blood pressure in vessels during a heart beat. Diastolic blood pressure is the pressure between heartbeats. A systolic or the diastolic blood pressure measurement higher than the accepted normal values for the age of the individual is classified as prehypertension or hypertension.

Hypertension has several sub-classifications including, hypertension stage I, hypertension stage II, and isolated systolic hypertension. Isolated systolic hypertension refers to elevated systolic pressure with normal diastolic pressure and is common in the elderly. These classifications are made after averaging a patient's resting blood pressure readings taken on two or more office visits. Individuals older than 50 years are classified as having hypertension if their blood pressure is consistently at least 140 mmHg systolic or 90 mmHg diastolic. Patients with blood pressures higher than 130/80 mmHg with concomitant presence of diabetes or kidney disease require further treatment.[4]

Hypertension is also classified as resistant if medications do not reduce blood pressure to normal levels.[4]

Exercise hypertension is an excessively high elevation in blood pressure during exercise.[5][6][7] The range considered normal for systolic values during exercise is between 200 and 230 mm Hg.[8] Exercise hypertension may indicate that an individual is at risk for developing hypertension at rest.[7][8]

[edit] Signs and symptoms

Mild to moderate essential hypertension is usually asymptomatic.[9]

[edit] Accelerated hypertension

Accelerated hypertension is associated with headache, drowsiness, confusion, vision disorders, nausea, and vomiting symptoms which are collectively referred to as hypertensive encephalopathy. Hypertensive encephalopathy is caused by severe small blood vessel congestion and brain swelling, which is reversible if blood pressure is lowered.[10]

[edit] Children

Some signs and symptoms are especially important in newborns and infants such as failure to thrive, seizures, irritability, lack of energy, and difficulty breathing.[11] In children, hypertension can cause headache, fatigue, blurred vision, nosebleeds, and facial paralysis.[11]

[edit] Secondary hypertension

Some additional signs and symptoms suggest that the hypertension is caused by disorders in hormone regulation. Hypertension combined with obesity distributed on the trunk of the body, accumlated fat on the back of the neck ('buffalo hump'), wide purple marks on the abdomen (abdominal striae), or the recent onset of diabetes suggests that an individual has a hormone disorder known as Cushing's syndrome. Hypertension caused by other hormone disorders such as hyperthyroidism, hypothyroidism, or growth hormone excess will be accompanied by additional symptoms specific to these disorders. For example, hyperthyrodism can cause weight loss, tremors, heart rate abnormalities, reddening of the palms, and increased sweating.[12] Signs and symptoms associated with growth hormone excess include coarsening of facial features, protrusion of the lower jaw, enlargement of the tongue,[13] excessive hair growth, darkening of the skin color, and excessive sweating.[14]:499. Other hormone disorders like hyperaldosteronism may cause less specific symptoms such as numbness, excessive urination, excessive sweating, electrolyte imbalances and dehydration, and elevated blood alkalinity.[15]

[edit] Pregnancy

Hypertension in pregnant women is known as pre-eclampsia. Pre-eclampsia can progress to a life-threatening condition called eclampsia, which is the development of protein in the urine, generalized swelling, and severe seizures. Other symptoms indicating that brain function is becoming impaired may precede these seizures such as nausea, vomiting, headaches, and vision loss.[16]

[edit] Causes

[edit] Essential hypertension

Essential hypertension is the most prevalent hypertension type, affecting 90-95% of hypertensive patients.[1] Although no direct cause has identified itself, there are many factors such as sedentary lifestyle,[17] stress, visceral obesity, potassium deficiency (hypokalemia),[17] obesity[18] (more than 85% of cases occur in those with a body mass index greater than 25),[19] salt (sodium) sensitivity,[20] alcohol intake,[21] and vitamin D deficiency that increase the risk of developing hypertension.[22][23] Risk also increases with aging,[24] some inherited genetic mutations,[25] and having a family history of hypertension.[26] An elevation of renin, an enzyme secreted by the kidney, is another risk factor,[27] as is sympathetic nervous system overactivity.[28] Insulin resistance which is a component of syndrome X, or the metabolic syndrome is also thought to contribute to hypertension.[27][29] Consuming foods that contain high fructose corn syrup may increase one's risk of developing hypertension.[30] Recent studies have implicated low birth weight as a risk factor for adult essential hypertension.[31]

[edit] Secondary hypertension

Secondary hypertension by definition results from an identifiable cause. This type is important to recognize since it's treated differently than essential hypertension, by treating the underlying cause of the elevated blood pressure. Hypertension results compromise or imbalance of the pathophysiological mechanisms, such as the hormone-regulating endocrine system, that regulate blood plasma volume and heart function. Many conditions cause hypertension, some are common and well recognized secondary causes such as Cushing's syndrome,[32] which is a condition where the adrenal glands overproduce the hormone cortisol.[32] In addition, hypertension is caused by other conditions that cause hormone changes such as hyperthyroidism, hypothyroidism, and adrenal gland cancer. Other common causes of secondary hypertension include kidney disease, obesity/metabolic disorder, pre-eclampsia during pregnancy, the congenital defect known as coarctation of the aorta, and certain prescription and illegal drugs.

[edit] Pathophysiology

A diagram explaining factors affecting arterial pressure

Most of the mechanisms associated with secondary hypertension are generally fully understood. However, those associated with essential (primary) hypertension are far less understood. What is known is that cardiac output is raised early in the disease course, with total peripheral resistance (TPR) normal; over time cardiac output drops to normal levels but TPR is increased. Three theories have been proposed to explain this:

It is also known that hypertension is highly heritable and polygenic (caused by more than one gene) and a few candidate genes have been postulated in the etiology of this condition.[35]

Recently, work related to the association between essential hypertension and sustained endothelial damage has gained popularity among hypertension scientists. It remains unclear however whether endothelial changes precede the development of hypertension or whether such changes are mainly due to long standing elevated blood pressures.

[edit] Diagnosis

Hypertension is generally diagnosed on the basis of a persistently high blood pressure. Usually this requires three separate sphygmomanometer (see figure) measurements at least one week apart. Initial assessment of the hypertensive patient should include a complete history and physical examination. Exceptionally, if the elevation is extreme, or if symptoms of organ damage are present then the diagnosis may be given and treatment started immediately.

Once the diagnosis of hypertension has been made, physicians will attempt to identify the underlying cause based on risk factors and other symptoms, if present. Secondary hypertension is more common in preadolescent children, with most cases caused by renal disease. Primary or essential hypertension is more common in adolescents and has multiple risk factors, including obesity and a family history of hypertension.[26] Laboratory tests can also be performed to identify possible causes of secondary hypertension, and determine if hypertension has caused damage to the heart, eyes, and kidneys. Additional tests for Diabetes and high cholesterol levels are also usually performed because they are additional risk factors for the development of heart disease require treatment.[1] Tests typically performed are classified as follows:

System Tests
Renal Microscopic urinalysis, proteinuria, serum BUN (blood urea nitrogen) and/or creatinine
Endocrine Serum sodium, potassium, calcium, TSH (thyroid-stimulating hormone).
Metabolic Fasting blood glucose, total cholesterol, HDL and LDL cholesterol, triglycerides
Other Hematocrit, electrocardiogram, and Chest X-ray
Sources: Harrison's principles of internal medicine[36] others[37][38][39][40][41][42]

Creatinine (renal function) testing is done to determine if kidney disease is present, which can be either the cause or result of hypertension. In addition, it provides a baseline measurement of kidney function that can be used to monitor for side-effects of certain antihypertensive drugs on kidney function. Additionally, testing of urine samples for protein is used as a secondary indicator of kidney disease. Glucose testing is done to determine if diabetes is present. Electrocardiogram (EKG/ECG) testing is done to check for evidence of the heart being under strain from high blood pressure. It may also show if there is thickening of the heart muscle (left ventricular hypertrophy) or has experienced a prior minor heart distubance such as a silent heart attack. A chest X-ray may be performed to look for signs of heart enlargement or damage to heart tissue.

[edit] Prevention

The degree to which hypertension can be prevented depends on a number of features including: current blood pressure level, sodium/potassium balance, detection and omission of environmental toxins, changes in end/target organs (retina, kidney, heart - among others), risk factors for cardiovascular diseases and the age at the time of diagnosis of prehypertenion or at risk for hypertension. A prolonged assessment period within which repeated measurements of blood pressure are taken provides the most accurate assessment of blood pressure levels. Following this, lifestyle changes are recommended to lower blood pressure, before the initiation of prescription drug therapy. The process of managing prehypertension according the guidelines of the British Hypertension Society suggest the following lifestyle changes;

[edit] Treatment

[edit] Lifestyle modifications

The first line of treatment for hypertension is the same as the recommended preventative lifestyle changes such as the dietary changes, physical exercise, and weight loss, which have all been shown to significantly reduce blood pressure in people with hypertension.[52] If hypertension is high enough to justify immediate use of medications, lifestyle changes are still recommended in conjunction with medication. Different programs aimed to reduce psychological stress such as biofeedback, relaxation or meditation are advertised to reduce hypertension. However, in general claims of efficacy are not supported by scientific studies, which have been in general of low quality.[53][54][55]

[edit] Medications

There are many classes of medications for treating hypertension, together called antihypertensives, which — by varying means — act by lowering blood pressure. Reduction of the blood pressure by 5–6 mmHg can decrease the risk of stroke by 40%, decrease the risk of heart disease by 15–20%, and reduce the likelihood of dementia, heart failure, and death.

The aim of treatment should be reduce blood pressure to <140/90 mmHg for most individuals, and lower individuals with diabetes or kidney disease (some medical professionals recommend keeping levels below 120/80 mmHg).[56] Each drug reduces systolic blood pressure by about 5–10 mmHg, so often multiple drugs are combined to achieve the goal blood pressure.

Commonly used prescription drugs include:[57]

Common combined prescription drug treatments:

[edit] Resistant

Guidelines for treating resistant hypertension have been published in the UK[57] and US.[63]

[edit] Complications

Diagram illustrating the main complications of persistent high blood pressure.

Hypertension is the most important risk factor for death in industrialized countries.[64] It increases hardening of the arteries[65] thus predisposes individuals to heart disease[66], peripheral vascular disease,[67], and strokes.[68] Types of heart disease that may occur include: heart attack[68], heart failure[69], and left ventricular hypertrophy[70] Other complications include:

[edit] Epidemiology

In the year 2000 it is estimated that nearly one billion people or ~26% of the adult population have hypertension worldwide.[73] It was common in both developed (333 million ) and undeveloped (639 million) countries.[73] However rates vary markedly in different regions with rates as low as 3.4% (men) and 6.8% (women) in rural India and as high as 68.9% (men) and 72.5% (women) in Poland.[74]

In 1995 it is estimated that 43 million people in the United States had hypertension or were taking antihypertensive medication, almost 24% of the adult population.[75] The prevalence of hypertension in the United States is increasing and reached 29% in 2004.[76][77] It is more common in blacks and less in whites and Mexican Americans, rates increase with age, and is greater in the southeastern United States. Hypertension is more prevalent in men (though menopause tends decrease this difference) and those of low socioeconomic status.[1]

Over 90—95% of adult hypertension is essential hypertension.[1] The most common cause of secondary hypertension is primary aldosteronism.[38] The incidence of exercise hypertension is reported to range from 1—10%.[8]

[edit] Pediatrics

The prevalence of high blood pressure in the young is increasing.[78] Most childhood hypertension, particularly in preadolescents, is secondary to an underlying disorder. Kidney disease is the most common (60—70%) cause of hypertension in children. Adolescents usually have primary or essential hypertension, which accounts for 85—95% of cases.[79].

[edit] History

Image of veins from Harvey's Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus

Some cite the writings of Sushruta in the 6th century BC as being the first mention of symptoms like those of hypertension.[80] Others propose even earlier descriptions dating as far as 2600 years before Christ. Main treatment for what was called the "hard pulse disease" consisted in reducing the quantity of blood in a subject by the sectioning of veins or the application of leeches.[81] Well known individuals such as The Yellow Emperor of China, Cornelius Celsus, Galen, or Hipocrates advocated for such treatments.[81]

Our modern understanding of hypertension began with the work of physician William Harvey (1578–1657), who was the first to describe correctly the systemic circulation of blood being pumped around the body by the heart in his book "De motu cordis". The basis for measuring blood pressure were established by Stephen Hales in 1733.[81] Initial descriptions of hypertension as a disease came among others from Thomas Young in 1808 and specially Richard Bright in 1836.[81] The first ever elevated blood pressure in a patient without kidney disease was reported by Frederick Mahomed (1849–1884).[82] It was not until 1904 that sodium restriction was advocated while a rice diet was popularized around 1940.[81] The first chemical for hypertension, Sodium thiocyanate, was used in 1900 but had many secondary effects.[81] Surgical and chemical sypathectomies were also used all over the 20th century.[81] Nevertheless the major advance was the appearance of effective diuretics after 1957 and other symptomatic medications in following years.[81]

[edit] Society and culture

[edit] Economics

The National Heart, Lung, and Blood Institute (NHLBI) estimated in 2002 that hypertension cost the United States $47.2 billion.[83]

High blood pressure is the most common chronic medical problem prompting visits to primary health care providers, yet it is estimated that only 34% of the 50 million American adults with hypertension have their blood pressure controlled to a level of <140/90 mm Hg [citation needed]. Thus, about two thirds of Americans with hypertension are at increased risk for heart disease. The medical, economic, and human costs of untreated and inadequately controlled high blood pressure are enormous. Adequate management of hypertension can be hampered by inadequacies in the diagnosis, treatment, and/or control of high blood pressure.[84] Health care providers face many obstacles to achieving blood pressure control from their patients, including resistance to taking multiple medications to reach blood pressure goals. Patients also face the challenges of adhering to medicine schedules and making lifestyle changes. Nonetheless, the achievement of blood pressure goals is possible, and most importantly, lowering blood pressure significantly reduces the risk of death due to heart disease, the development of other debilitating conditions, and the cost associated with advanced medical care.[85],[86][87]

[edit] Awareness

Graph showing, prevalence of awareness, treatment and control of hypertension compared between the four studies of NHANES[76]

The World Health Organization attributes hypertension, or high blood pressure, as the leading cause of cardiovascular mortality. The World Hypertension League (WHL), an umbrella organization of 85 national hypertension societies and leagues, recognized that more than 50% of the hypertensive population worldwide are unaware of their condition.[88] To address this problem, the WHL initiated a global awareness campaign on hypertension in 2005 and dedicated May 17 of each year as World Hypertension Day (WHD). Over the past three years, more national societies have been engaging in WHD and have been innovative in their activities to get the message to the public. In 2007, there was record participation from 47 member countries of the WHL. During the week of WHD, all these countries – in partnership with their local governments, professional societies, nongovernmental organizations and private industries – promoted hypertension awareness among the public through several media and public rallies. Using mass media such as Internet and television, the message reached more than 250 million people. As the momentum picks up year after year, the WHL is confident that almost all the estimated 1.5 billion people affected by elevated blood pressure can be reached.[89]

[edit] References

  1. ^ a b c d e Carretero OA, Oparil S (January 2000). "Essential hypertension. Part I: definition and etiology". Circulation 101 (3): 329–35. PMID 10645931. http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=10645931. 
  2. ^ Secondary hypertension, Mayo Foundation for Medical Education and Research (2008)[1], Retrieved May 10, 2010
  3. ^ Pierdomenico SD, Di Nicola M, Esposito AL, et al. (June 2009). "Prognostic Value of Different Indices of Blood Pressure Variability in Hypertensive Patients". American Journal of Hypertension 22 (8): 842–7. doi:10.1038/ajh.2009.103. PMID 19498342. 
  4. ^ a b c Chobanian AV, Bakris GL, Black HR, et al. (December 2003). "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure". Hypertension 42 (6): 1206–52. doi:10.1161/01.HYP.0000107251.49515.c2. PMID 14656957. 
  5. ^ Jetté M, Landry F, Blümchen G (April 1987). "Exercise hypertension in healthy normotensive subjects. Implications, evaluation and interpretation". Herz 12 (2): 110–8. PMID 3583204. 
  6. ^ Pickering TG (April 1987). "Pathophysiology of exercise hypertension". Herz 12 (2): 119–24. PMID 2953661. 
  7. ^ a b Rost R, Heck H (April 1987). "[Exercise hypertension--significance from the viewpoint of sports]" (in German). Herz 12 (2): 125–33. PMID 3583205. 
  8. ^ a b c Klaus D (April 1987). "[Differential therapy of exercise hypertension]" (in German). Herz 12 (2): 146–55. PMID 3583208. 
  9. ^ Pitts SR, Adams RP (February 1998). "Emergency department hypertension and regression to the mean". Annals of Emergency Medicine 31 (2): 214–8. doi:10.1016/S0196-0644(98)70309-9. PMID 9472183. 
  10. ^ Papadakis, Maxine A.; McPhee, Stephen J. (2008). Current Medical Diagnosis and Treatment 2009 (Current Medical Diagnosis and Treatment). McGraw-Hill Professional. ISBN 0-07-159124-9. 
  11. ^ a b Rodriguez-Cruz, Edwin; Ettinger, Leigh M (April 6, 2010). "Hypertension". eMedicine Pediatrics: Cardiac Disease and Critical Care Medicine. Medscape. http://emedicine.medscape.com/article/889877-overview. Retrieved 2009-06-16. 
  12. ^ Lee, Stephanie L; Ananthakrishnan, Sonia (April 26, 2010). "Hyperthyroidism". eMedicine Endocrinology. Medscape. http://emedicine.medscape.com/article/121865-overview. Retrieved 2009-06-16. 
  13. ^ Khandwala, Hasnain M (February 13, 2009). "Acromegaly". eMedicine Endocrinology. Medscape. http://emedicine.medscape.com/article/116366-overview. Retrieved 2009-06-16. 
  14. ^ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology (10th ed.). Saunders. ISBN 0721629210. 
  15. ^ Chrousos, George P; Lafferty, Antony (March 4, 2009). "Hyperaldosteronism". eMedicine Pediatrics: General Medicine. Medscape. http://emedicine.medscape.com/article/920713-overview. Retrieved 2009-06-16. 
  16. ^ Gibson, Paul (July 30, 2009). "Hypertension and Pregnancy". eMedicine Obstetrics and Gynecology. Medscape. http://emedicine.medscape.com/article/261435-overview. Retrieved 2009-06-16. 
  17. ^ a b Kyrou I, Chrousos GP, Tsigos C (November 2006). "Stress, visceral obesity, and metabolic complications". Annals of the New York Academy of Sciences 1083: 77–110. doi:10.1196/annals.1367.008. PMID 17148735. 
  18. ^ Wofford MR, Hall JE (2004). "Pathophysiology and treatment of obesity hypertension". Current Pharmaceutical Design 10 (29): 3621–37. PMID 15579059. http://www.bentham-direct.org/pages/content.php?CPD/2004/00000010/00000029/0007B.SGM. 
  19. ^ Haslam DW, James WP (2005). "Obesity". Lancet 366 (9492): 1197–209. doi:10.1016/S0140-6736(05)67483-1. PMID 16198769. 
  20. ^ Lackland DT, Egan BM (August 2007). "Dietary salt restriction and blood pressure in clinical trials". Curr. Hypertens. Rep. 9 (4): 314–9. doi:10.1007/s11906-007-0057-8. PMID 17686383. 
  21. ^ Djoussé L, Mukamal KJ (June 2009). "Alcohol consumption and risk of hypertension: does the type of beverage or drinking pattern matter?". Revista Española De Cardiología 62 (6): 603–5. PMID 19480755. http://www.revespcardiol.org/cardio/62/603. 
  22. ^ Tuohimaa P (March 2009). "Vitamin D and aging". The Journal of Steroid Biochemistry and Molecular Biology 114 (1-2): 78–84. doi:10.1016/j.jsbmb.2008.12.020. PMID 19444937. 
  23. ^ Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF (2008). "Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?". J. Am. Coll. Cardiol. 52 (24): 1949–56. doi:10.1016/j.jacc.2008.08.050. PMID 19055985. 
  24. ^ Kosugi T, Nakagawa T, Kamath D, Johnson RJ (February 2009). "Uric acid and hypertension: an age-related relationship?". J Hum Hypertens 23 (2): 75–6. doi:10.1038/jhh.2008.110. PMID 18754017. 
  25. ^ Dickson ME, Sigmund CD (July 2006). "Genetic basis of hypertension: revisiting angiotensinogen". Hypertension 48 (1): 14–20. doi:10.1161/01.HYP.0000227932.13687.60. PMID 16754793. 
  26. ^ a b Luma GB, Spiotta RT (May 2006). "Hypertension in children and adolescents". Am Fam Physician 73 (9): 1558–68. PMID 16719248. 
  27. ^ a b Segura J, Ruilope LM (October 2007). "Obesity, essential hypertension and renin-angiotensin system". Public Health Nutrition 10 (10A): 1151–5. doi:10.1017/S136898000700064X. PMID 17903324. 
  28. ^ Rahmouni K, Correia ML, Haynes WG, Mark AL (January 2005). "Obesity-associated hypertension: new insights into mechanisms". Hypertension 45 (1): 9–14. doi:10.1161/01.HYP.0000151325.83008.b4. PMID 15583075. 
  29. ^ Sorof J, Daniels S (October 2002). "Obesity hypertension in children: a problem of epidemic proportions". Hypertension 40 (4): 441–7. doi:10.1161/01.HYP.0000032940.33466.12. PMID 12364344. http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=12364344. Retrieved 2009-06-03. 
  30. ^ "High fructose intake from added sugars: An independent association with hypertension". ScienceDaily. 2009-11-09. http://www.sciencedaily.com/releases/2009/10/091029211521.htm. Retrieved 2010-05-02. 
  31. ^ Uchiyama M (August 2008). "[Mild hypertension in children]" (in Japanese). Nippon Rinsho 66 (8): 1477–80. PMID 18700545. 
  32. ^ a b Dodt C, Wellhöner JP, Schütt M, Sayk F (January 2009). "[Glucocorticoids and hypertension]" (in German). Der Internist 50 (1): 36–41. doi:10.1007/s00108-008-2197-6. PMID 19096817. 
  33. ^ Pimenta E, Oparil S (2009). "Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors". Vascular Health and Risk Management 5 (1): 453–63. PMID 19475781. 
  34. ^ Takahashi H (August 2008). "[Sympathetic hyperactivity in hypertension]" (in Japanese). Nippon Rinsho. Japanese Journal of Clinical Medicine 66 (8): 1495–502. PMID 18700548. 
  35. ^ Sagnella GA, Swift PA (June 2006). "The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure". Current Pharmaceutical Design 12 (14): 2221–2234. doi:10.2174/138161206777585157. PMID 16787251. 
  36. ^ Loscalzo, Joseph; Fauci, Anthony S.; Braunwald, Eugene; Dennis L. Kasper; Hauser, Stephen L; Longo, Dan L. (2008). Harrison's principles of internal medicine. McGraw-Hill Medical. ISBN 0-07-147691-1. 
  37. ^ Padwal RS, Hemmelgarn BR, Khan NA, et al. (May 2009). "The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk". The Canadian Journal of Cardiology 25 (5): 279–86. PMID 19417858. 
  38. ^ a b Mulatero P, Bertello C, Verhovez A, et al. (June 2009). "Differential diagnosis of primary aldosteronism subtypes". Current Hypertension Reports 11 (3): 217–23. doi:10.1007/s11906-009-0038-1. PMID 19442332. 
  39. ^ Padwal RJ, Hemmelgarn BR, Khan NA, et al. (June 2008). "The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk". The Canadian Journal of Cardiology 24 (6): 455–63. PMID 18548142. 
  40. ^ Padwal RS, Hemmelgarn BR, McAlister FA, et al. (May 2007). "The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk". The Canadian Journal of Cardiology 23 (7): 529–38. PMID 17534459. 
  41. ^ Hemmelgarn BR, McAlister FA, Grover S, et al. (May 2006). "The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk". The Canadian Journal of Cardiology 22 (7): 573–81. PMID 16755312. 
  42. ^ Hemmelgarn BR, McAllister FA, Myers MG, et al. (June 2005). "The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk". The Canadian Journal of Cardiology 21 (8): 645–56. PMID 16003448. 
  43. ^ Elley CR, Arroll B (2002). "Review: aerobic exercise reduces systolic and diastolic blood pressure in adults". ACP J. Club 137 (3): 109. PMID 12418849. http://www.acpjc.org/Content/137/3/Issue/ACPJC-2002-137-3-109.htm. 
  44. ^ Klaus D, Böhm M, Halle M, et al. (May 2009). "[Restriction of salt intake in the whole population promises great long-term benefits]" (in German). Deutsche Medizinische Wochenschrift (1946) 134 Suppl 3: S108–18. doi:10.1055/s-0029-1222573. PMID 19418415. 
  45. ^ Appel LJ, Moore TJ, Obarzanek E et al. (April 1997). "A clinical trial of the effects of dietary patterns on blood pressure". New England Journal of Medicine 336 (16): 1117–24. doi:10.1056/NEJM199704173361601. PMID 9099655. 
  46. ^ Addison WLT (1928 March). "The use of sodium chloride, potassium chloride, sodium bromide, and potassium bromide in cases of arterial hypertension which are amenable to potassium chloride". Can Med Assoc J 18 (3): 281–5. 
  47. ^ Benson, Herbert (1975). The Relaxation Response. New York: Morrow. ISBN 0688029558. 
  48. ^ "Biofeedback". Mayo Clinic. 2006. http://www.mayoclinic.org/news2006-rst/3334.html. 
  49. ^ "Device-Guided Paced Breathing Lowers Blood Pressure, Blood Pressure". Press release. 2006-05-16. http://www.emaxhealth.com/106/5912.html. Retrieved 2009-07-03. 
  50. ^ Elliott WJ, Izzo JL (2006). "Device-guided breathing to lower blood pressure: case report and clinical overview". MedGenMed 8 (3): 23. PMID 17406163. PMC 1781326. http://www.medscape.com/viewarticle/539099. 
  51. ^ Nakao M, Yano E, Nomura S, Kuboki T (January 2003). "Blood pressure-lowering effects of biofeedback treatment in hypertension: a meta-analysis of randomized controlled trials". Hypertens. Res. 26 (1): 37–46. doi:10.1291/hypres.26.37. PMID 12661911. 
  52. ^ Blumenthal JA, Babyak MA, Hinderliter A, et al. (January 2010). "Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study". Arch. Intern. Med. 170 (2): 126–35. doi:10.1001/archinternmed.2009.470. PMID 20101007. 
  53. ^ Greenhalgh J, Dickson R, Dundar Y (October 2009). "The effects of biofeedback for the treatment of essential hypertension: a systematic review". Health Technol Assess 13 (46): 1–104. doi:10.3310/hta13460. PMID 19822104. 
  54. ^ Rainforth MV, Schneider RH, Nidich SI, Gaylord-King C, Salerno JW, Anderson JW (December 2007). "Stress reduction programs in patients with elevated blood pressure: a systematic review and meta-analysis". Curr. Hypertens. Rep. 9 (6): 520–8. PMID 18350109. 
  55. ^ Ospina MB, Bond K, Karkhaneh M, et al. (June 2007). "Meditation practices for health: state of the research". Evid Rep Technol Assess (Full Rep) (155): 4. PMID 17764203. 
  56. ^ Shaw, Gina (2009-03-07). "Prehypertension: Early-stage High Blood Pressure". WebMD. http://www.webmd.com/content/article/73/88927.htm. Retrieved 2009-07-03. 
  57. ^ a b "CG34 Hypertension - quick reference guide" (PDF). National Institute for Health and Clinical Excellence. 28 June 2006. http://www.nice.org.uk/nicemedia/pdf/cg034quickrefguide.pdf. Retrieved 2009-03-04. 
  58. ^ Kragten JA, Dunselman PHJM. Nifedipine gastrointestinal therapeutic system (GITS) in the treatment of coronary heart disease and hypertension. Expert Rev Cardiovasc Ther 5 (2007):643-653. FULL TEXT!
  59. ^ Piller LB, Davis BR, Cutler JA, et al. (November 2002). "Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone". Curr Control Trials Cardiovasc Med 3 (1): 10. doi:10.1186/1468-6708-3-10. PMID 12459039. 
  60. ^ Mayor S (2006). "NICE removes beta blockers as first line treatment for hypertension". BMJ 333 (7557): 8. doi:10.1136/bmj.333.7557.8-a. PMID 16809680. PMC 1488775. http://www.bmj.com/cgi/content/full/333/7557/8-a. 
  61. ^ Presentation on Direct Renin Inhibitors as Antihypertensive Drugs
  62. ^ Widimský J (February 2009). "[The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension]" (in Czech). Vnitr?ní Lékar?ství 55 (2): 123–30. PMID 19348394. 
  63. ^ Calhoun DA, Jones D, Textor S, et al. (June 2008). "Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research". Hypertension 51 (6): 1403–19. doi:10.1161/HYPERTENSIONAHA.108.189141. PMID 18391085. 
  64. ^ Novo S, Lunetta M, Evola S, Novo G (January 2009). "Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events". Current Drug Targets 10 (1): 20–5. PMID 19149532. http://www.bentham-direct.org/pages/content.php?CDT/2009/00000010/00000001/0003J.SGM. 
  65. ^ Riccioni G (2009). "The effect of antihypertensive drugs on carotid intima media thickness: an up-to-date review". Current Medicinal Chemistry 16 (8): 988–96. PMID 19275607. http://www.bentham-direct.org/pages/content.php?CMC/2009/00000016/00000008/0006C.SGM. 
  66. ^ Agabiti-Rosei E (September 2008). "From macro- to microcirculation: benefits in hypertension and diabetes". Journal of Hypertension 26 Suppl 3: S15–21. doi:10.1097/01.hjh.0000334073.04705.04 (inactive 2010-05-21). PMID 18815511. 
  67. ^ Singer DR, Kite A (June 2008). "Management of hypertension in peripheral arterial disease: does the choice of drugs matter?". European Journal of Vascular and Endovascular Surgery 35 (6): 701–8. doi:10.1016/j.ejvs.2008.01.007. PMID 18375152. 
  68. ^ a b White WB (May 2009). "Defining the problem of treating the patient with hypertension and arthritis pain". The American Journal of Medicine 122 (5 Suppl): S3–9. doi:10.1016/j.amjmed.2009.03.002. PMID 19393824. 
  69. ^ Pedrinelli R, Dell'Omo G, Talini E, Canale ML, Di Bello V (February 2009). "Systemic hypertension and the right-sided cardiovascular system: a review of the available evidence". Journal of Cardiovascular Medicine (Hagerstown, Md.) 10 (2): 115–21. doi:10.2459/JCM.0b013e32831da941 (inactive 2010-05-21). PMID 19377378. 
  70. ^ Giacchetti G, Turchi F, Boscaro M, Ronconi V (April 2009). "Management of primary aldosteronism: its complications and their outcomes after treatment". Current Vascular Pharmacology 7 (2): 244–49. doi:10.2174/157016109787455716. PMID 19356005. 
  71. ^ Rodríguez NA, Zurutuza A (2008). "[Ophthalmological manifestations of arterial hypertension"] (in Spanish; Castilian). Anales Del Sistema Sanitario De Navarra 31 Suppl 3: 13–22. PMID 19169291. http://recyt.fecyt.es/index.php/ASSN/article/view/5209/4401. Retrieved 2009-06-21. 
  72. ^ Zeng C, Villar VA, Yu P, Zhou L, Jose PA (April 2009). "Reactive oxygen species and dopamine receptor function in essential hypertension". Clinical and Experimental Hypertension 31 (2): 156–78. doi:10.1080/10641960802621283. PMID 19330604. 
  73. ^ a b Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005). "Global burden of hypertension: analysis of worldwide data". Lancet 365 (9455): 217–23. doi:10.1016/S0140-6736(05)17741-1. PMID 15652604. 
  74. ^ Kearney PM, Whelton M, Reynolds K, Whelton PK, He J (January 2004). "Worldwide prevalence of hypertension: a systematic review". J. Hypertens. 22 (1): 11–9. PMID 15106785. 
  75. ^ Burt VL, Whelton P, Roccella EJ, et al. (March 1995). "Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991". Hypertension 25 (3): 305–13. PMID 7875754. http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=7875754. Retrieved 2009-06-05. 
  76. ^ a b Burt VL, Cutler JA, Higgins M, et al. (July 1995). "Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991". Hypertension 26 (1): 60–9. PMID 7607734. http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=7607734. Retrieved 2009-06-05. 
  77. ^ Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S (July 2007). "Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004". Journal of the American Geriatrics Society 55 (7): 1056–65. doi:10.1111/j.1532-5415.2007.01215.x. PMID 17608879. 
  78. ^ Falkner B (May 2009). "Hypertension in children and adolescents: epidemiology and natural history". Pediatr. Nephrol.. doi:10.1007/s00467-009-1200-3. PMID 19421783. 
  79. ^ "Hypertension in Children and Adolescents". Hypertension in Children and Adolescents. American Academy of Family Physician. 2006. http://www.aafp.org/afp/20060501/1558.html. Retrieved 2007-07-24. 
  80. ^ Dwivedi, Girish & Dwivedi, Shridhar (2007). History of Medicine: Sushruta – the Clinician – Teacher par Excellence. National Informatics Centre (Government of India).
  81. ^ a b c d e f g h Esunge PM (October 1991). "From blood pressure to hypertension: the history of research". J R Soc Med 84 (10): 621. PMID 1744849. 
  82. ^ edited by J.D. Swales. (1995). Manual of hypertension. Oxford: Blackwell Science. pp. xiii. ISBN 0-86542-861-1. 
  83. ^ "What is Hypertension? - WrongDiagnosis.com". http://www.wrongdiagnosis.com/h/hypertension/basics.htm. 
  84. ^ Alcocer L, Cueto L (June 2008). "Hypertension, a health economics perspective". Therapeutic Advances in Cardiovascular Disease 2 (3): 147–55. doi:10.1177/1753944708090572. PMID 19124418. http://tak.sagepub.com/cgi/pmidlookup?view=long&pmid=19124418. Retrieved 2009-06-20. 
  85. ^ William J. Elliott (October 2003). "The Economic Impact of Hypertension". The Journal of Clinical Hypertension 5 (4): 3–13. doi:10.1111/j.1524-6175.2003.02463.x. 
  86. ^ Theodoratou D, Maniadakis N, Fragoulakis V, Stamouli E (2009). "Analysis of published economic evaluations of angiotensin receptor blockers". Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese 50 (2): 105–18. PMID 19329412. http://www.hellenicjcardiol.org/archive/full_text/2009/2/2009_2_105.pdf. Retrieved 2009-06-20. 
  87. ^ Coca A (2008). "Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers)". Clinical Drug Investigation 28 (4): 211–20. doi:10.2165/00044011-200828040-00002. PMID 18345711. 
  88. ^ Chockalingam A (May 2007). "Impact of World Hypertension Day". The Canadian Journal of Cardiology 23 (7): 517–9. PMID 17534457. 
  89. ^ Chockalingam A (June 2008). "World Hypertension Day and global awareness". The Canadian Journal of Cardiology 24 (6): 441–4. PMID 18548140. 

[edit] Further reading

[edit] External links


This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Hypertension".

Need An Altace Attorney?

First Name Last Name Email Address State
Has Your Health Been Negatively Affected?

Please Describe the Injury

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Want to contact an Altace attorney in District of Columbia?...Get a free case evaluation from one of our Altace attorneys in District of Columbia now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Altace Case - Submit Your Information Below

Do you need legal assistance with your Altace case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *
Last name *
Email Address *
Phone Number *
()  -

State *
Legal Issue * DrugWatch: Altace Change
Was There an Injury?
Please Describe The Injury

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website [more...]

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.